Clinical Trial Update: Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial exploring pegylated liposomal doxorubicin as induction therapy for lymphoma-induced hemophagocytic lymphohistiocytosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Hemophagocytic Lymphohistiocytosis | Phase 3 | Status: UNKNOWN